厄达替尼治疗尿路上皮癌效果怎么样？

Becoming the first urothelial cancer targeted drug approved for marketing in the world. On April 12, 2019, the FDA announced accelerated approval of erdafitinib, a tablet sold under the trade name Balversa®, for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma whose disease has progressed despite platinum-based chemotherapy.

How effective is erdafitinib in the treatment of urothelial cancer?

The clinical trial was evaluable for efficacy in 87 patients who had progressed before or after at least one line of chemotherapy and had at least one of the following genetic alterations: FGFR3 gene mutations (R248C, S249C, G370C, Y373C) or FGFR gene fusions (FGFR3-tacc3, FGFR3-baiap2l1, FGFR2-BICC1, FGFR2-CASP7).

The main indicators evaluated in this clinical trial are objective response rate (the proportion of tumor shrinkage by more than 30%) and duration of response. The treatment results were: the objective response rate (ORR) was 32.2%, of which complete response (CR) was 2.3% and partial response (PR) was 29.9%; the median duration of response (DoR) was 5.4 months.

The most common adverse reactions for the treatment of urothelial cancer in trials include: stomatitis (56%), fatigue (54%), diarrhea (47%), dry mouth (45%), onychomycosis (41%), and poor appetite (38%) , dysgeusia (37%), dry skin (34%), constipation (28%), dry eye syndrome (28%), hand-foot syndrome (26%), hair loss (26%), abdominal pain (23%), nausea (21%), etc.

Note: The above information comes from the Internet and is compiled and edited by Medical Companion Travel (please correct me if there are any errors or omissions). It is only to provide information on the latest drugs on the market in the world and help Chinese patients understand the latest international new drug trends. It is only for internal discussion among medical staff and does not serve as any basis for medication. For specific medication guidelines, please consult the attending physician.

Recommended related articles: